Skip to content
Important Safety Information Back to Glaukos.com

Connect with a doctor who performs the only FDA-approved cross-linking procedure and can discuss referrals for imaging.

Find a doctor Find an iLink® Provider

Lead the investigation and refer patients for iLink® corneal cross-linking*

As an iDetective, be the first on the case to detect progressive keratoconus. Even subtle clues merit a prompt referral for further diagnostics and an iLink® cross-linking consultation to slow or halt the progression of this sight-threatening disease. Following treatment with iLink®, iDetectives continue to maintain their patients’ vision with regular checkups and glasses or contact lenses.

70% of keratoconus

presents through optometry, making you the first line of defense.1

The real risk of keratoconus to patients’ vision

Left untreated, up to

1 in 5 patients

may require a
corneal transplant2

Of those patients,

greater than half

may require multiple transplants within 20 years3

Blow the whistle on keratoconus

Keratoconus could be hiding in plain sight. Be on the lookout for covert clues in the patient history and examination findings that could lead you to suspect keratoconus, and be ready to sound the alarm. It’s time to #FollowTheClues.

 Get Started

Mission Possible: Keep your patients on the right track

In the keratoconus journey, it’s up to you to ensure that patients you suspect have keratoconus get the optimized care they deserve.

Magnifying Glass icon
Detection

Collect subtle clues during the comprehensive eye exam.
Handshake icon
Referral

Refer KC suspects for a cross-linking consultation.
Contacts case icon
Management

Solve their vision needs.

Discover what to expect during post–cross-linking management

 Get Started

Help solve the case:
When in doubt, refer out

iDetectives can spot the clues and promptly refer patients with suspected progressive keratoconus to a corneal specialist who can confirm whether treatment with iLink® is appropriate.

  • Delaying treatment of progressive keratoconus may result in continued progression and loss of vision4
  • Early intervention may reduce strain on patients’ financial resources and increase their quality of life
  • iLink® offers patients peace of mind knowing their vision can be preserved by slowing or halting disease progression with an FDA-approved device

Both the American Academy of Ophthalmology and the Cornea Society recommend cross-linking for the treatment of progressive keratoconus.

 Find a Doctor
Pie chart - Over 95% of commercially insured lives are eligible for insurance coverage for iLink®.

Stop keratoconus in its tracks

Only iLink®:

  • Is an FDA-approved corneal cross-linking procedure
  • Is widely covered by insurance
  • Slows or halts progressive keratoconus with proven technology, efficacy,
    and safety
  • Is backed by 20 years of science to achieve the right formulation
Timepiece illustration

94% of iLink® corneal cross-linking cases have been shown to slow or halt the progression of keratoconus.5

Make a referral you can trust—your patients will thank you for it

If it’s not iLink®, it’s not approved by the FDA. Find a specialist who offers FDA-approved iLink®. Watch out for false flags! Don’t be double-crossed by unapproved cross-linking drugs and devices.

After you refer a patient, stay on the case to solve their vision needs. Early intervention with iLink® helps unlock the refractive toolbox and may be able to prevent patients from becoming intolerant to contact lenses.

Be your patients’ iLink® advocate

ENSURE THEY UNDERSTAND THAT:

  • iLink® is covered by the majority of commercial insurance providers
  • iLink® is a minimally invasive outpatient procedure
  • Patients are typically awake during the 1-hour procedure
  • Some discomfort is possible during immediate recovery
  • iLink® is not intended to improve their vision
  • You will monitor their recovery and vision needs after treatment

*Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® system, the iLink® corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.†6

†Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® system is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

REFERENCES

  1. Eisenberg JS. First treatment for keratoconus itself. Optometry Times. June 1, 2012. Accessed April 25, 2023.
    https://www.optometrytimes.com/view/first-treatment-keratoconus-itself.
  2. Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology. 2006;113(9):1633-1638.
  3. Maharana PK, Agarwal K, Jhanji V, Vajpayee RB. Deep anterior lamellar keratoplasty for keratoconus: a review. Eye Contact Lens. 2014;40(6):382-389.
  4. Romano V, Vinciguerra R, Arbabi EM, et al. Progression of keratoconus in patients while awaiting corneal cross-linking: a prospective clinical study.
    J Refract Surg. 2018;34(3):177-180.
  5. Hersh PS, Stulting RD, Muller D, Durrie DS, Rajpal RK; United States Crosslinking Study Group. United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment. Ophthalmology. 2017;124(9):1259-1270.
  6. Photrexa. Prescribing information. Avedro; 2022.

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.*1

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, click View Prescribing Information button below to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Reference

1. Photrexa Prescribing Information. Burlington, MA: Avedro, a Glaukos company 2022.

View Prescribing Information